GlassScriptPhysician profile
Marc A Munoz
NPI 1013186956
$1,264.10
in general payments reported to CMS, 2019-2025
15 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.67 · 2022: $468 · 2023: $300 · 2024: $197 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.28 | 2022-2025 | Relistor |
| Electronic Waveform Lab, INC. | $208.10 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $145.17 | 2021-2024 | Belbuca |
| Scilex Pharmaceuticals INC. | $142.79 | 2022-2024 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $122.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $113.65 | 2022 | |
| Grt US Holding, INC. | $69.95 | 2022 | |
| Pfizer INC. | $46.12 | 2023 | |
| Bioventus LLC | $41.21 | 2023 | Durolane |
| Si-Bone, INC. | $30.32 | 2022-2023 | |
| Boston Scientific Corporation | $24.54 | 2025 | Intracept |
| Ibsa Pharma INC. | $24.36 | 2023 | Tirosint, Licart |
| Merz Pharmaceuticals, LLC | $21.71 | 2022 | |
| Nalu Medical, INC. | $16.40 | 2022 | |
| Hikma Pharmaceuticals USA | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.